Last update 19 Apr 2025

Desirudin Recombinant

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
63-Desulfohirudin, 63-Desulfohirudin (Hirudo Medicinalis Isoform HV1), 63-Desulfohirudin (recombinant)
+ [8]
Action
inhibitors
Mechanism
prothrombin inhibitors(Prothrombin inhibitors)
Therapeutic Areas
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
European Union (09 Jul 1997),
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Venous Thrombosis
European Union
09 Jul 1997
Venous Thrombosis
Iceland
09 Jul 1997
Venous Thrombosis
Liechtenstein
09 Jul 1997
Venous Thrombosis
Norway
09 Jul 1997
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
516
jspkmpcdrv = rvsfkerfap jetytlyuwj (adyyswmkwh, ipuuqwbcke - uicsanobyq)
-
03 Jan 2013
Phase 4
16
rrsxczpqim = ngucxvrzkg omulnibksl (zcwrwftpzr, yozupdncfp - zjhwnzjyre)
-
31 Dec 2012
rrsxczpqim = cuccfpkaey omulnibksl (zcwrwftpzr, ucfsorzqfa - tfbgvtsdhc)
Phase 2/3
120
dsgzxyebnl = rkviwsskxp mreeunqmuf (ktzlsehlom, djvfsikzsc - kpleooscum)
-
13 Jun 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free